[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341357-105":59,"doc-detail-341357-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","detecting-the-flj22447-lncrna-in-ovarian-cancer-with-cyclopentane-modified-fit-pnas-cpfit-pnas","Detecting the FLJ22447 lncRNA in Ovarian Cancer with Cyclopentane-Modified FIT-PNAs (cpFIT-PNAs)","","Ovarian cancer is among the most lethal gynecologic malignancies and is commonly diagnosed at advanced stages, creating a need for diagnostic tools for earlier detection. This work targets RNA-based biomarkers using FLJ22447 lncRNA, which is over-expressed in ovarian cancer cells and cancer-associated fibroblasts (CAFs). The study designs and synthesizes cyclopentane-modified FIT-PNAs (cpFIT-PNAs), evaluates them against FIT-PNA and different cell-penetrating peptides, and demonstrates improved sensing of FLJ22447 in OVCAR8 cells and CAFs. Incubation with CLIP6-cpFIT-PNA decreases FLJ22447 levels and cell viability, indicating theranostic potential.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/detecting-the-flj22447-lncrna-in-ovarian-cancer-with-cyclopentane-modified-fit-pnas-cpfit-pnas/341357/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/detecting-the-flj22447-lncrna-in-ovarian-cancer-with-cyclopentane-modified-fit-pnas-cpfit-pnas/341357.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is detecting ovarian cancer early difficult, and why is FLJ22447 lncRNA chosen?","Question",{"text":112,"@type":113},"Ovarian cancer often presents vague, non-specific symptoms and lacks effective and sensitive screening. FLJ22447 lncRNA is over-expressed in ovarian cancer and CAFs, supporting its use as an RNA biomarker for early-stage detection.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What are cpFIT-PNAs and how do they work for RNA detection?",{"text":117,"@type":113},"cpFIT-PNAs are cyclopentane-modified forced intercalation peptide nucleic acid probes designed to fluoresce upon hybridization to their complementary RNA target sequence. The cyclopentane modification improves RNA-sensing performance compared with FIT-PNA.",{"name":119,"@type":110,"acceptedAnswer":120},"How did the study improve cellular uptake, and what was the outcome in OVCAR8 cells?",{"text":121,"@type":113},"The cell-penetrating peptide (CPP) was selected either as four L-lysines or a higher-uptake CPP (CLIP6). Combining CLIP6 with cpFIT-PNA produced superior FLJ22447 sensing in both OVCAR8 cells and CAFs and significantly reduced FLJ22447 levels and cell viability (about 60%).","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341357,1791321555,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","biomolecules  \nArticle  \nDetecting the FLJ22447 lncRNA in Ovarian Cancer with Cyclopentane-Modified FIT-PNAs (cpFIT-PNAs)  \nSheethal Thomas Mannully 1, Rawan Mahajna 1, Huda Nazzal 1, Salam Maree 1, Hongchao Zheng 2, Daniel H. Appella 2, Reuven Reich 1 and Eylon Yavin 1, *  \nCitation: Mannully, S.T.; Mahajna, R.; Nazzal, H.; Maree, S.; Zheng, H.; Appella, D.H.; Reich, R.; Yavin, E. Detecting the FLJ22447 lncRNA in Ovarian Cancer with CyclopentaneModified FIT-PNAs (cpFIT-PNAs) . Biomolecules 2024, 14, 609. [https://](https://)[ ](https://)[doi.org/10.3390/biom14060609](doi.org/10.3390/biom14060609)  \nAcademic Editor: William Cho  \nReceived: 1 April 2024  \nRevised: 13 May 2024  \nAccepted: 16 May 2024  \nPublished: 22 May 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Hadassah Ein-Kerem, Jerusalem 91120, Israel; [sheethal.thomas@mail.huji.ac.il](sheethal.thomas@mail.huji.ac.il) (S.T.M.); [rawan.mahajna1@mail.huji.ac.il](rawan.mahajna1@mail.huji.ac.il) (R.M.); [huda.nazzal@mail.huji.ac.il](huda.nazzal@mail.huji.ac.il) (H.N.); [salam.maree@mail.huji.ac.il](salam.maree@mail.huji.ac.il) (S.M.); [reuvenr@ekmd.huji.ac.il](reuvenr@ekmd.huji.ac.il) (R.R.)  \n2 Synthetic Bioactive Molecules Section, Laboratory of Bioorganic Chemistry (LBC), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 8 Center Drive, Room 404, Bethesda, MD 20892, USA; [hongchao.zheng@nih.gov](hongchao.zheng@nih.gov) (H.Z.); [appellad@niddk.nih.gov](appellad@niddk.nih.gov) (D.H.A.)  \n* Correspondence: [eylony@ekmd.huji.ac.il](eylony@ekmd.huji.ac.il)  \nAbstract: Ovarian cancer (OC) is one of the most lethal gynecologic cancers that is typically diagnosed at the very late stage of disease progression. Thus, there is an unmet need to develop diagnostic probes for early detection of OC. One approach may rely on RNA as a molecular biomarker. In this regard, FLJ22447 lncRNA is an RNA biomarker that is over-expressed in ovarian cancer (OC) and in cancer-associated fibroblasts (CAFs) . CAFs appear early on in OC as they provide a metastatic niche for OC progression. FIT-PNAs (forced intercalation-peptide nucleic acids) are DNA analogs that are designed to fluoresce upon hybridization to their complementary RNA target sequence. In recent studies, we have shown that the introduction of cyclopentane PNAs into FIT-PNAs (cpFITPNA) results in superior RNA sensors. Herein, we report the design and synthesis of cpFIT-PNAs for the detection of this RNA biomarker in living OC cells (OVCAR8) and in CAFs. cpFIT-PNA was compared to FIT-PNA and the cell-penetrating peptide (CPP) of choice was either a simple one (four L-lysines) or a CPP with enhanced cellular uptake (CLIP6) . The combination of CLIP6 with cpFIT-PNA resulted in a superior sensing of FLJ22447 lncRNA in OVCAR8 cells as well as in CAFs. Moreover, incubation of CLIP6-cpFIT-PNA in OVCAR8 cells leads to a significant decrease (ca. 60%) in FLJ22447 lncRNA levels and in cell viability, highlighting the potential theranostic use of such molecules.  \nKeywords: cyclopentane modified FIT-PNA; FLJ22447 lncRNA; ovarian cancer; cancer-associated fibroblasts; cell-penetrating peptide; RNA biomarker  \n1. Introduction  \nOvarian cancer is the second most common malignancy in women over the age of 40, and the most fatal gynecologic cancer with five-year survival rates below 50%[1] . The low survival rates are due to the poor diagnosis of the disease, and many women are present with advanced disease (stage 3 or stage 4) at diagnosis when malignant cells have already disseminated to the perito","cbCaivIh2Lv4aR8u","https://ap.wps.com/l/cbCaivIh2Lv4aR8u","pdf",2879552,17,"English","# Introduction\n## Ovarian cancer diagnosis challenges\n## Role of lncRNA biomarkers\n## FLJ22447 and CAFs\n## PNA and FIT-PNA sensing concept","[{\"question\":\"Why is detecting ovarian cancer early difficult, and why is FLJ22447 lncRNA chosen?\",\"answer\":\"Ovarian cancer often presents vague, non-specific symptoms and lacks effective and sensitive screening. FLJ22447 lncRNA is over-expressed in ovarian cancer and CAFs, supporting its use as an RNA biomarker for early-stage detection.\"},{\"question\":\"What are cpFIT-PNAs and how do they work for RNA detection?\",\"answer\":\"cpFIT-PNAs are cyclopentane-modified forced intercalation peptide nucleic acid probes designed to fluoresce upon hybridization to their complementary RNA target sequence. The cyclopentane modification improves RNA-sensing performance compared with FIT-PNA.\"},{\"question\":\"How did the study improve cellular uptake, and what was the outcome in OVCAR8 cells?\",\"answer\":\"The cell-penetrating peptide (CPP) was selected either as four L-lysines or a higher-uptake CPP (CLIP6). Combining CLIP6 with cpFIT-PNA produced superior FLJ22447 sensing in both OVCAR8 cells and CAFs and significantly reduced FLJ22447 levels and cell viability (about 60%).\"}]","Detecting the FLJ22447 lncRNA in Ovarian Cancer with Cyclopentane-Modified FIT-PNAs (cpFIT-PNAs) | PDF",1790041641,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b3b17e4553907b89b898ab83c8ee2e43.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3ebd9cda559f2d6c087a9e550fbbced0.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/48286d56877267127a6cdf8621ca2d5a.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42f00338d3c574ee81a8c1d56c131d05.webp",980,1385]